On January 4, 2022 Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, reported that members of its senior management team will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 3:00 PM ET (Press release, Lyell Immunopharma, JAN 4, 2022, View Source [SID1234609997]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, the Company will highlight its:

Pipeline of CAR, TIL and TCR product candidates across multiple solid tumor indications of high unmet medical need including LYL797, a CAR T-cell therapy for solid tumors. Lyell expects to begin screening patients for its Phase 1 clinical trial of LYL797 by the end of the first quarter, with initial data presentation expected in 2023.
Novel platform technologies – Gen-R and Epi-R – designed to enable T cells to resist exhaustion, self-renew and proliferate to outlast and eradicate solid tumors.
LyFE Manufacturing Center, built to provide greater control over Lyell’s supply chain and maximize efficiencies in cell product production time, cost and quality. LyFE is qualified in compliance with the U.S. Food and Drug Administration’s Current Good Manufacturing Practices (cGMP) and has completed successful engineering runs at scale.
A live webcast of the presentation can be accessed through the Investors section of the Company’s website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days following the presentation date.